In bone metastatic breast and prostate cancer, enhanced activity of the histone methyltransferase enhancer of zeste 2 (EZH2) reprogrammes disseminated cells into a more stem-like phenotype, and elevates their capacity to seed other sites in mice, which can be prevented with an EZH2 inhibitor [21]. This evidence concerns the gene EZH2 and prostate carcinoma.